ReserpineS1601

Reserpine (5 mg/kg s.c.) reduces extracellular DA levels to 4% of basal values in intact rats. Reserpine (5 mg/kg s.c.) diminishes L-DOPA (50 mg/kg i.p.)-induced increases in extracellular dopamine levels to 16% of those obtained in denervated animals not pretreated with reserpine in 6-hydroxydopamine-lesioned rats. ^[2] Reserpine causes a marked depletion of vasopressin/oxytocin-neu-rophysin-like immunoreactivity (LI) and CRH-L1 in the median eminence of the rat. ^[3] Reserpine significantly restores performance on the delayed response task in monkeys. Reserpine has little effect on performance of a visual discrimination task, a reference memory task which does not depend on the prefrontal cortex. ^[4] Reserpine injection (one dose of 1 mg/kg s.c.) every other day for 3 days causes a significant increase in vacuous chewing, tongue protrusion and duration of facial twitching in rats, compared to the control. Reserpine results in a decreased glutamate uptake in the subcortical parts of rats. ^[5] Reserpine (5 mg/kg) significantly increases vacuous jaw movements, and also reduces rearing behavior in all age groups of rats. ^[6]